Hong Kong suspends use of Pfizer-BioNTech vaccine over defective lids

Hong Kong suspended use of the vaccine created by Pfizer and BioNTech Wednesday after its Chinese distributor informed the city that one batch had defective bottle lids.

The only vaccine now available to residents is China's Sinovac vaccine

All community centres in Hong Kong administering the Pfizer vaccine have temporarily suspended vaccinations. (Vincent Yu/The Associated Press)

Hong Kong suspended use of the vaccine created by Pfizer and BioNTech Wednesday after its Chinese distributor informed the city that one batch had defective bottle lids.

The city's government said the suspension was immediate while the matter is investigated by vaccine distributor Fosun Pharma and BioNTech, the German company that created the vaccine with American pharmaceutical firm Pfizer. 

BioNTech and Fosun Pharma have not found any reason to believe the product is unsafe, according to the statement. However, vaccinations will be halted as a preventive and safety measure.

The defective lids were found on vaccines from batch number 210102. A separate batch of vaccines, 210104, will also not be administered.

Macau also said Wednesday that residents would not receive vaccinations from the affected batch.

Suspension a precautionary measure, officials say

The vaccines from the batch comprise a total of 585,000 doses, with the other batch number 210104 holding 758,000 doses, according to Hong Kong's Director of Health Constance Chan.

Although about 150,000 doses from the batch 210102 have been administered in the city so far, officials said during a media briefing Wednesday that the vaccines were safe to use despite the packaging defects, and that suspending the vaccination was a precautionary measure. Batch number 210104 remains in the warehouse and has not been used.

Chan said that there were over 40 instances when medical personnel found defective packaging, such as cracks on the vaccine bottles or leakages when the vaccine was diluted with saline before being administered. None of these vaccines were given to residents and were thrown away, officials said.

"Fosun has promised to carry out an immediate investigation so they are going to approach the manufacturer in Germany to look into their plant," Chan said.

"When the vaccines arrive in Hong Kong, they will have a review of the whole logistics chain to see if that's the cause of the current situation."

She said that officials are urging manufacturers to give a report as soon as possible to check if the batches of vaccines in Hong Kong can be used, otherwise the manufacturers will have to deliver another batch of shots as soon as possible.

Residents who are slated to receive their second dose starting on Saturday should get the second shot administered as soon as possible, if new vaccines arrive in Hong Kong after the recommended 19- to 42-day window following the first dose.

BioNTech launches investigation

BioNTech said in a statement that it had launched an investigation to find the "root cause" of the vaccine packaging issues. It said the investigation would look into the entire supply chain of the vaccines from the time the vials were filled all the way to their handling at vaccination centres.

"At this point, we have no reason to believe there is any safety risk posed to the population," the statement said.

The company also said that no other region aside from Hong Kong and Macau had been supplied with doses from the affected batch.

Fosun Pharma said in a filing to the Hong Kong stock exchange that it received notice from BioNTech regarding the packaging defects on Tuesday night and informed Hong Kong and Macau authorities on Wednesday to temporarily suspend the vaccines.

All community centres in Hong Kong administering the vaccines have temporarily suspended vaccinations and residents who already made appointments for Wednesday need not proceed to the centres, the government said.

A vial of Pfizer-BioNTech COVID-19 vaccine is seen at the Strathcona Paper Centre in Napanee, Ont., on March 15, 2021. (Lars Hagberg/The Canadian Press)

Sinovac now only vaccine available in Hong Kong

The suspension of the jab means the only vaccine currently offered to residents is China's Sinovac vaccine. The two vaccines are the only ones that were offered to residents in Hong Kong.

German expatriate Jannis Partsafas was among a group of people who received the BioNTech shot ahead of the suspension.

"I got vaccinated this morning at 8:30 a.m. before the news went public about the vaccine suspension, and heard the news when I was on my way home," said 32-year-old Partsafas, who works in the sporting goods industry.

"I'm not very concerned about the safety, but I am worried that this may mean more people will turn down the option of getting vaccinated in Hong Kong, which would impact herd immunity and the lifting of social-distancing measures," he said.

Some residents who had appointments Wednesday morning stood in line outside a community centre administering the vaccinations in the city's Sai Ying Pun neighbourhood at about 10:30 a.m. They eventually left the centre when it became apparent that no vaccines would be administered.

As of 8 p.m. Tuesday, 403,000 people have received vaccines in the city, of which 150,200 had received the first dose of the BioNTech vaccine, compared with 252,800 who had received the Sinovac jab.

Add some “good” to your morning and evening.

A variety of newsletters you'll love, delivered straight to you.

Sign up now